Peter Hillmen, MD, PhD, from St. James’ University Hospital, Leeds, UK gives an overview of the RESONATE-2 trial (NCT01722487), a randomized Phase III trial of ibtrutinib in chronic lymphocytic leukemia (CLL). The trial compared inbrutinib to chlorambucil and showed a significant improvement in progression-free survival (PFS), which was the primary endpoint, and further an overall survival (OS) advantage for patients on the ibrutinib arm. Overall, ibrutinib was well tolerated according to Prof Hillmen.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.